Form 4: RA Capital Reduces Vor Biopharma Stake by 464K Shares

RA Capital Management and its affiliated funds, including directors Peter Kolchinsky and Rajeev Shah, sold 464,025 shares of Vor Biopharma Inc. common stock over three days in October 2025 under a Rule 10b5-1 plan.

Summary

• RA Capital Management, L.P., along with its affiliated funds (RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P.), and managing members Peter Kolchinsky and Rajeev Shah, reported the sale of Vor Biopharma Inc. common stock.
• A total of 464,025 shares were sold across multiple transactions on October 15, 16, and 17, 2025.
• The sales were executed at weighted average prices ranging from $28.85 to $31.20 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• The reported share counts reflect a 1-for-20 reverse stock split effected by Vor Biopharma Inc. on September 18, 2025.
• Following these transactions, RA Capital Healthcare Fund, L.P. beneficially owns 1,503,172 shares, and RA Capital Nexus Fund, L.P. beneficially owns 15,104 shares.

Sentiment

Score: 3

Explanation: The significant insider selling by a major institutional investor and directors, even if pre-planned, generally indicates a less positive outlook or a strategic reduction in exposure, which is a negative signal for the stock.

Positives

• No direct positives for the company are indicated by this insider selling report.

Negatives

• Significant reduction in ownership by a major institutional investor and director, potentially signaling a lack of confidence or a strategic portfolio rebalancing.
• Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market and may put downward pressure on the stock price.

Risks

• Investor sentiment could be negatively impacted by the significant insider selling, leading to decreased demand for the stock.
• The reduction in stake by a major institutional investor might be interpreted as a signal of concerns regarding future company performance or valuation.

Future Outlook

This filing, a Form 4, does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund'). The general partner of the Adviser is RA Capital Management GP, LLC (the 'Adviser GP'), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.
• Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.

Industry Context

Insider selling, particularly by significant institutional investors and directors, is a common occurrence in the biotechnology sector. While often pre-planned via 10b5-1 arrangements for liquidity or portfolio rebalancing, substantial sales can sometimes be interpreted by the market as a signal of reduced confidence in the company's near-term prospects or valuation, especially in a volatile industry like biotech where clinical trial results and regulatory approvals are key drivers.

Related Party Transactions

• The reported sales of common stock were conducted by RA Capital Management, L.P. and its affiliated funds, which are 10% owners of Vor Biopharma Inc.
• Peter Kolchinsky and Rajeev Shah, managing members of RA Capital Management GP, LLC, are also directors of Vor Biopharma Inc. and are listed as reporting persons.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The reduction in stake by a major institutional investor could influence other institutional investors' perceptions and investment decisions regarding Vor Biopharma Inc.

Next Steps

• No specific future actions, events, or milestones for Vor Biopharma Inc. are mentioned in this insider transaction report.

Key Dates

Recommendation

While the significant insider selling by RA Capital Management and its affiliated directors is a negative signal, the transactions were conducted under a Rule 10b5-1 plan, which suggests they were pre-scheduled and not necessarily indicative of new, adverse information. However, such a substantial reduction in holdings by a major investor warrants caution. Investors should hold their positions and monitor future company developments and market sentiment closely, as this selling could exert downward pressure on the stock.

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Selling, Form 4, Stock Split, 10b5-1 Plan, Biotechnology, Healthcare Investment